Pui | Treatment of Acute Leukemias | Buch | 978-0-89603-834-9 | sack.de

Buch, Englisch, 562 Seiten, Format (B × H): 232 mm x 275 mm, Gewicht: 1828 g

Reihe: Current Clinical Oncology

Pui

Treatment of Acute Leukemias

New Directions for Clinical Research
2003. Auflage 2002
ISBN: 978-0-89603-834-9
Verlag: Humana Press

New Directions for Clinical Research

Buch, Englisch, 562 Seiten, Format (B × H): 232 mm x 275 mm, Gewicht: 1828 g

Reihe: Current Clinical Oncology

ISBN: 978-0-89603-834-9
Verlag: Humana Press


International experts not only review the state-of-the-art in managing children and adults with acute leukemia, but also debate the pros and cons of current controversial and problematic issues. The book summarizes the best diagnostic and treatment practices for acute leukemias in children, adolescents, and adults. Among the therapies discussed are methotrexate, asparaginase, antipurines, epipodophyllotoxins, hematopoietic stem cell transplantation, hematopoietic growth factors, and immunotherapy.

Pui Treatment of Acute Leukemias jetzt bestellen!

Zielgruppe


Professional/practitioner


Autoren/Hrsg.


Weitere Infos & Material


I: Diagnosis, Classification, and Prognosis.- 1 Classification of Acute Leukemias: Perspective 1.- 2 Classification of Acute Leukemias: Perspective 2.- II: Chemotherapeutic Strategies.- 3 Biology and Treatment of Infant Leukemias: Perspective 1.- 4 Biology and Treatment of Acute Leukemias in Infants: Perspective 2.- 5 Treatment of Childhood Acute Lymphoblastic Leukemia.- 6 Treatment of Childhood Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute ALL Consortium Perspective.- 7 Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Lessons Learned and Future Directions.- 8 Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Children’s Cancer Group Trials.- 9 Treatment of Adult Acute Lymphoblastic Leukemia: Perspective 1.- 10 Treatment of Adult Acute Lymphoblastic Leukemia: Perspective 2.- 11 Central Nervous System—Directed Therapy for Acute Lymphoblastic Leukemia.- 12 Diagnosis, Prophylaxis, and Treatment of Central Nervous System Involvement in Acute Lymphoblastic Leukemia.- 13 Treatment of Relapsed Acute Lymphoblastic Leukemia: Perspective 1.- 14 Treatment of Relapsed Acute Lymphoblastic Leukemia: Perspective 2.- 15 Treatment of B-Cell Acute Lymphoblastic Leukemia: Perspective 1.- 16 Treatment of B-Cell Acute Lymphoblastic Leukemia: Perspective 2.- 17 Treatment of Acute Myeloid Leukemia in Children.- 18 Treatment of Childhood Acute Myeloid Leukemia.- I. Acute Myeloid Leukemia in Adults.- 19 Therapy of Acute Myeloid Leukemia in Adults.- 20 Treatment of Adult Acute Myelogenous Leukemia.- J. Acute Promyelocytic Leukemia.- 21 Acute Promyelocytic Leukemia: Perspective 1.- 22 Acute Promyelocytic Leukemia: Perspective 2.- K. Childhood Leukemias in Underprivileged Countries.- 23 Treatment of Childhood Leukemias inUnderprivileged Countries.- 24 How to Confront the Problem of Treatment of Childhood Leukemias in Underprivileged Populations.- III: Antileukemic Drugs.- 25 Rationale for High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia.- 26 Role of Methotrexate in the Treatment of Acute Lymphoblastic Leukemia.- 27 Asparaginase.- 28 Asparaginase Treatment.- 29 Antipurines in Childhood Acute Lymphoblastic Leukemia.- 30 Antipurines.- 31 Etoposide in Acute Leukemias: Therapeutic and Pharmacokinetic Considerations.- 32 Etoposide and Teniposide: Clinical Applications with a Focus on Leukemia.- IV: Hematopoietic Stem Cell Transplantation.- 33 Hematopoietic Stem Cell Transplantation: Perspective 1.- 34 Hematopoietic Stem Cell Transplantation: Perspective 2.- V: Biologic Treatments.- 35 Hematopoietic Growth Factors in Patients with Acute Leukemia.- 36 Hematopoietic Growth Factor Treatment in Leukemia.- 37 Immunotherapy of Leukemia.- 38 Therapy of Acute Leukemia with Monoclonal Antibodies and Immunoconjugates.- VI: Drug Resistance.- 39 Drug Resistance in Acute Leukemias.- 40 Drug Resistance in Acute Leukemia.- VII: Minimal Residual Disease.- 41 Minimal Residual Disease.- 42 Molecular Monitoring of Minimal Residual Disease.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.